Barely Significant
← all excerpts

Preclinical evaluation of a novel triple-acting PIM/PI3K/mTOR inhibitor, IBL-302, in breast cancer.

Oncogene · 2020 · PMC7118022 · PMID 32042115

Europe PMCDOI
1
hedged sentence
0.0500
closest p · 1.0× alpha
0.0500
boldest claim

The sentences

highly significantp < 0.05actually significant
In the BT-474 xenograft study, in comparison with the vehicle control group, the IBL-302 (50 mg/kg) treated group demonstrated a highly significant reduction ( p < 0.05) in the tumour volumes from day 12 to day 21 (Fig. 4a ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.